Tag:

NovaDigm Therapeutics

Latest Headlines

Latest Headlines

Little NovaDigm races Pfizer, Glaxo in drive to develop MRSA vaccine

FierceBiotech | September 17, 2012
The lethal spread of MRSA in hospitals and other public places has been driving a number of programs aimed at finding a new vaccine capable of preventing tens of thousands of deaths each year.

First 'cross-kingdom' vax effective in PhI

May 10, 2012 | By
NovaDigm Therapeutics is developing a vaccine that could work against both bacteria and fungi, and could even combat resistant bacteria such as MRSA. The company presented Phase I results at the 15th Annual Conference on Vaccine Research.
Related Tags
Press Releases
  • Philips launches BlueControl, the world's first wearable blue LED light therapy device to treat skin disease psoriasis vulgaris
  • Philips secures 510(k) clearance to market the first clinical applications for its new digital health platform
  • The Greek company “ANTAEA Medical Services Ltd.” won the lawsuit against “ATLAS Medical Services Ltd.” and Özdemir Hiçdurmaz
  • Flowonix Submits PMA Supplements for Prometra Implantable Pump System
  • Nine-valent HPV Vaccine May Prevent Nearly 90 Percent of Cervical Cancers
  • More Press Releases
Sponsored Links